PT-141 (Bremelanotide): The Evidence on Libido and Arousal
An FDA-approved drug for low desire in premenopausal women — and a popular off-label experiment. What the trials actually show.
Most drugs that affect sexual function work on blood flow. PT-141, also known as bremelanotide, is unusual: it acts in the brain. It is a melanocortin receptor agonist — a synthetic cyclic peptide derived from alpha-melanocyte-stimulating hormone that activates central melanocortin receptors (notably MC4R) rather than dilating blood vessels the way PDE5 inhibitors do. It is one of the few compounds in this space to clear a regulatory bar, and that, plus a steady off-label following, makes it worth a careful, hype-free look.
What it’s approved for, and what the trials showed
The FDA approved bremelanotide (brand name Vyleesi) in 2019 for “premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)” — distressing low desire not explained by another cause. The dose is a 1.75 mg subcutaneous injection taken as needed, at least 45 minutes before anticipated activity.
The pivotal evidence came from two identical, 24-week, randomized, double-blind, placebo-controlled phase 3 trials (the RECONNECT program, studies 301 and 302), published in Obstetrics & Gynecology in 2019 by Kingsberg and colleagues. Of 1,267 premenopausal women randomized, the effect on the trial’s co-primary measures was statistically significant but modest: desire improved by an integrated 0.35 (P<.001) and distress related to low desire fell by 0.33 (P<.001) versus placebo.
The honest read: this is a genuine, statistically significant effect on a hard-to-treat condition — not a transformation. The placebo response was substantial, the absolute gains were small, and the endpoints were questionnaire scores rather than a hard physiological measure.
What the data does and doesn’t cover
- Premenopausal women with HSDD: the population actually studied, where modest benefit is documented.
- Men, and use for erectile function or arousal: off-label and far less rigorously established; earlier development never led to approval there.
- Casual or recreational use: essentially unstudied in controlled settings.
Side effects and the off-label reality
The most common adverse reaction in the trials was nausea, reported by about 40% of treated women per the FDA label, with flushing (around 20%) and headache (around 11%) also common. Each dose produces a transient rise in blood pressure (the label cites maximal increases of roughly 6 mmHg systolic and 3 mmHg diastolic) and a small drop in heart rate, usually resolving within 12 hours — which is why the drug is contraindicated in people with uncontrolled hypertension or known cardiovascular disease. Consistent with its melanocortin activity, focal skin hyperpigmentation (face, gums, breasts) was reported in about 1% of women receiving up to 8 doses per month, and was not always confirmed to resolve after stopping.
Off-label, the compound circulates well outside that studied context — different doses, different populations, unregulated sourcing — with none of the safety or efficacy footing the approved indication has.
The takeaway
PT-141 is a rare thing: a centrally acting compound with a real, vetted indication. But even where it is approved, the effect is modest, nausea is common, and the cardiovascular and pigmentation cautions are concrete. Outside that narrow approved use — in men, for arousal, at self-chosen doses — you are in territory the trials simply did not map. Treat the approval as evidence for one specific use, not a blanket endorsement.